1. Fuster V., Rydén L.E., Cannom D.S. et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114(7):e257-e354.
2. Roden D.M. Antiarrhythmic drugs: from mechanisms to clinical practice. Heart 2000;84(3):339-46.
3. Zimetbaum P. Amiodarone for Atrial Fibrillation. N Engl J Med 2007;356(9):935- 41.
4. Blomström-Lundqvist C., Scheinman M.M., Aliot E.M. et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/AmericanHeart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation 2003;108(15):1871-909.
5. Basson C.T. A molecular basis for Wolff–Parkinson–White syndrome. N EnglJ Med 2001;344(24):1861-4.
6. Gollob M.H., Green M.S., Tang A.S-L. et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 2001;344:1823-31.
7. Basavarajaiah S., Shah A., Sharma S. Sudden cardiac death in young athletes.Heart 2007;93(3):287-9.
8. Wren C. Sudden death in children and adolescents. Heart 2002;88(4):426-31.
9. Диагностика и лечение фибрилляции предсердий. Рекомендации комитета экспертов Всероссийского научного общества кардиологов. Кардиоваскулярная терапия и профилактика 2005;4(4 Приложение 1):1-30.
10. Boriani G., Biffi M., Frabetti L. et al. Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White syndrome with atrial fibrillation. Am Heart J 1996;131(6):1214-6.
11. Feld G.K., Nademanee K., Stevenson W. et al. Clinical and electrophysiologic effects of amiodarone in patients with atrialfibrillation complicating theWolff-Parkin�son-White syndrome. Am Heart J 1988;115(1 Pt 1):102-7.
12. Kappenberger L.J., Fromer M.A., Steinbrunn W., Shenasa M. Efficacy of amiodarone in the Wolff-Parkinson-White syndrome with rapid ventricular response via accessory pathway during atrial fibrillation. Am J Cardiol 1984;54(3):330- 5.
13. Perticone F., Cuda G., Spadea F. et al. Malignant ventricular arrhythmia in the Wolff-Parkinson-White syndrome during amiodarone treatment. Clin Cardiol 1987;10(8):477-80.
14. Schützenberger W., Leisch F., Gmeiner R. Enhanced accessory pathway conduction following intravenous amiodarone in atrial fibrillation. A case report. Int J Cardiol 1987;16(1):93-5.
15. Tijunelis M.A.,Herbert M.E. Myth: Intravenous amiodarone is safe in patients with atrial fibrillation and Wolff-Parkinson-White syndrome in the emergency department. CJEM 2005;7(4):262-5.
16. Vitale P., De Stefano R., Auricchio A. Possible danger of rapid intravenous amiodarone in re-entry tachycardia in subjects with Wolff-Parkinson-White syndrome (in Italian). G Ital Cardiol 1986;16(11):969-74.
